Head-to-head evidence
Cariprazine (Vraylar) vs QLM1016
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D3/D2 receptor (partial agonist) · full Schizophrenia pipeline
Cariprazine (Vraylar)
Marketed by AbbVie and partners
NCT01104766 · Phase 3 · completed
The trial randomized 617 participants to cariprazine 3 mg, cariprazine 6 mg, aripiprazole 10 mg, or placebo, with participants, investigators, and outcome assessors masked. The prespecified clinical primary endpoint, change in PANSS total score at week 6, was significantly improved with both cariprazine doses versus placebo (p=0.0044 and p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT03817502 (registry estimate)
QLM1016
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cariprazine (Vraylar)'s landscape · QLM1016's landscape